Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Idera Pharmaceuticals Q4 EPS $(0.08) Up From $(2.11) YoY

Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.08) per share. This is a 96.21 percent increase over losses of $(2.11) per share from the same period last year.

byBenzinga Newsdesk

March 31, 2022

1 minute read

Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.08) per share. This is a 96.21 percent increase over losses of $(2.11) per share from the same period last year.

Keybanc Downgrades WalkMe to Sector Weight

By Benzinga Newsdesk

May 24, 4:15 AM

Keybanc analyst Michael Turits downgrades WalkMe (NASDAQ:WKME) from Overweight to Sector Weight.

WKME

Raymond James Maintains Outperform on ScanSource, Raises Price Target to $40

By Benzinga Newsdesk

August 25, 7:21 AM

Raymond James analyst Adam Tindle maintains ScanSource (NASDAQ:SCSC) with a Outperform and raises the price target from $35 to $40.

SCSC

Moleculin Granted FDA Fast Track Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme

By Benzinga Newsdesk

December 7, 9:47 AM

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,

MBRX